A detailed history of Janus Henderson Group PLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 91,341 shares of IOVA stock, worth $927,111. This represents 0.0% of its overall portfolio holdings.

Number of Shares
91,341
Previous 92,472 1.22%
Holding current value
$927,111
Previous $1.37 Million 46.57%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$7.78 - $14.19 $8,799 - $16,048
-1,131 Reduced 1.22%
91,341 $732,000
Q1 2024

May 15, 2024

SELL
$7.59 - $17.47 $113 - $262
-15 Reduced 0.02%
92,472 $1.37 Million
Q4 2023

Feb 14, 2024

SELL
$3.3 - $8.89 $165 - $444
-50 Reduced 0.05%
92,487 $751,000
Q3 2023

Nov 14, 2023

BUY
$4.44 - $8.79 $390 - $773
88 Added 0.1%
92,537 $421,000
Q2 2023

Aug 14, 2023

BUY
$5.36 - $9.06 $213,440 - $360,778
39,821 Added 75.67%
92,449 $650,000
Q1 2023

May 15, 2023

BUY
$5.53 - $8.22 $158,069 - $234,960
28,584 Added 118.88%
52,628 $321,000
Q4 2022

Feb 14, 2023

SELL
$5.62 - $10.0 $5 - $10
-1 Reduced -0.0%
24,044 $153,000
Q3 2022

Nov 14, 2022

SELL
$9.53 - $13.11 $228 - $314
-24 Reduced 0.1%
24,045 $231,000
Q2 2022

Aug 15, 2022

BUY
$6.38 - $18.33 $433 - $1,246
68 Added 0.28%
24,069 $265,000
Q1 2022

May 16, 2022

BUY
$12.38 - $19.1 $198 - $305
16 Added 0.07%
24,001 $399,000
Q4 2021

Feb 14, 2022

BUY
$16.55 - $27.63 $396,951 - $662,705
23,985 New
23,985 $458,000
Q2 2021

Aug 16, 2021

SELL
$16.33 - $33.07 $1.28 Million - $2.59 Million
-78,211 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$28.67 - $52.59 $1.73 Million - $3.17 Million
60,207 Added 334.41%
78,211 $2.48 Million
Q4 2020

Feb 16, 2021

BUY
$28.04 - $50.26 $504,832 - $904,881
18,004 New
18,004 $834,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.6B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.